GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
L

LTR Pharma LTP.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

0.46

+8.33%

Close of 9 Nov 2026, in AUD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About LTR Pharma

Its shares trade on ASX under the ticker LTP.AX. It has been listed since 11 December 2023. In the fiscal year to 30 June 2026, it reported revenue of A$183,928 and a net loss of A$14.2m. At that date it held total assets of A$20.9m and shareholders' equity of A$20.3m.

LTR Pharma Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Brisbane, Queensland. The company went IPO on 2023-12-11. LTR Pharma Limited is an Australia-based clinical-stage biopharmaceutical company. The firm is focused on holistically improving men’s health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction (ED). Its lead product SPONTAN is set apart from existing ED therapies by its mechanism of action-intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body supporting even and rapid absorption of the drug, empowering it to work in 10 minutes or less. SPONTAN (SDS-089) is a novel intranasal drug (PDE5) delivery platform for Erectile Dysfunction.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
11 Dec 2023

Leadership

Pay as last reported

  • Mr. Rodne LeeExecutive Chairman of the Board, since 2020
  • Ms. Shelby ColemanCompany Secretary
  • Dr. Julian ChickNon-Executive Independent Director
  • Ms. Maja McguireNon-Executive Independent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • LTR Pharma Ltd is a clinical-stage biopharmaceutical company focused on men's health.
  • The company's lead product SPONTAN uses intranasal delivery for rapid ED treatment.
  • SPONTAN works in 10 minutes or less due to rapid absorption in the nasal cavity.

Weaknesses

  • The company is clinical-stage with no commercialized products yet.
  • The IPO occurred in December 2023, indicating early-stage operations.
  • The company operates in a competitive pharmaceutical sector.

Opportunities

  • SPONTAN's intranasal delivery technology differentiates it from existing ED therapies.
  • The focus on holistic men's health may attract a growing market segment.
  • The company could expand its product pipeline beyond ED treatments.

Threats

  • Competition from established pharmaceutical companies in the ED market.
  • Regulatory hurdles for new drug approvals in the pharmaceutical industry.
  • Dependence on the success of SPONTAN for early-stage company growth.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.